“…1 The PR antagonist mifepristone (RU-486) is prescribed for termination of pregnancy and also offers promise for the treatment of endometriosis, uterine fibroids, and breast cancer. 2 Recently, non-steroidal PR antagonists and partial agonists have been identified with improved reproductive tissue safety profiles. 3,4 Nevertheless, new chemotypes that are amenable to high-throughput synthesis are useful to further structural understanding of PR modulation.…”